Natural killer cells and other innate lymphoid cells in cancer (Q57395724)

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Recognition and Regulation of T Cells by NK Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Dendritic cell editing by natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Type 2 innate lymphoid cells drive CD4+ Th2 cell responses

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Type 2 Innate Lymphocytes Actuate Immunity Against Tumours and Limit Cancer Metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Innate lymphoid cells and the MHC.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Biology of natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Differential tumor surveillance by natural killer (NK) and NKT cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Low Circulating Natural Killer Cell Counts are Associated With Severe Disease in Patients With Common Variable Immunodeficiency

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Natural killer cells and cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Pharyngeal carcinoma and natural killer cell activity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Natural killer cells and metastases from pharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Roles of alpha(4) integrins/VCAM-1 and LFA-1/ICAM-1 in the binding and transendothelial migration of T lymphocytes and T lymphoblasts across high endothelial venules

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

CIS is a potent checkpoint in NK cell-mediated tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Inhibition of Natural Killer Cell Cytotoxicity by Interleukin-6: Implications for the Pathogenesis of Macrophage Activation Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Interleukin-12 and -23 Control Plasticity of CD127(+) Group 1 and Group 3 Innate Lymphoid Cells in the Intestinal Lamina Propria

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

NK cell-derived interferon-γ orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Survivin is regulated by interleukin-4 in colon cancer stem cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Interleukin-13 and its receptors in colorectal cancer (Review).

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

EGF receptor trafficking: consequences for signaling and cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

IL-12 drives functional plasticity of human group 2 innate lymphoid cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Innate lymphoid cells: major players in inflammatory diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Microbiota: a key orchestrator of cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

A catch-22: Interleukin-22 and cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

A distinct innate lymphoid cell population regulates tumor-associated T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Licensing of natural killer cells by host major histocompatibility complex class I molecules

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Human NK cell education by inhibitory receptors for MHC class I.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Immunological off-target effects of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

CD56bright NK cells exhibit potent antitumor responses following IL-15 priming

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Optimization of human NK cell manufacturing: Fully-automated separation, improved <i>ex vivo </i>expansion using IL-21 with autologous feeder cells and generation of anti-CD123-CAR-expressing effector cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Interleukin-17D mediates tumor rejection through recruitment of natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

NK cell heparanase controls tumor invasion and immune surveillance

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

The biology of innate lymphoid cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Surface NK receptors and their ligands on tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Receptors for HLA class-I molecules in human natural killer cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Mouse Ly49 NK receptors: balancing activation and inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Mapping of NKp46(+) Cells in Healthy Human Lymphoid and Non-Lymphoid Tissues

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

RORγt⁺ innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Recognition strategies of group 3 innate lymphoid cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Evidence of innate lymphoid cell redundancy in humans

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Transforming Growth Factor-β Signaling Guides the Differentiation of Innate Lymphoid Cells in Salivary Glands

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Effect of tumor cells and tumor microenvironment on NK-cell function.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Impact of oncogenic pathways on evasion of antitumour immune responses.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Prognostic value of intratumoral natural killer cells in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Impact of immune parameters on long-term survival in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

EMT and dissemination precede pancreatic tumor formation

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Early dissemination seeds metastasis in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Mechanism of early dissemination and metastasis in Her2+ mammary cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Control of Metastasis by NK Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

A novel pro-angiogenic function for interferon-γ-secreting natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

PD-1 regulates KLRG1+ group 2 innate lymphoid cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021

Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41577-018-0061-Z

7 January 2021